protein
| interacting with EGFP in all stages of mitosis |
|
interacting with TSG101 (downregulated TSG101 in a post-transcriptional manner) |
|
forms a complex with PI3K and can activate PI3K activity |
|
associates with the KIF23-RACGAP1 centralspindlin complex |
|
linking RACGAP1 through a cellular mechanism which, in turn, controls the midbody structure and membrane fusion at the terminal stage of cytokinesis |
|
PLK1 activity negatively regulates CEP55 to ensure orderly abscission factor recruitment and ensures that this occurs only once cell contraction has completed |
|
TP53-PLK1-CEP55 axis in which TP53 negatively regulates expression of CEP55, through PLK1 which, in turn, is a positive regulator of CEP55 protein stability |
|
associates with and is phosphorylated by PLK1 during mitosis (tight regulation of CEP55 protein levels by TP53 is mediated by PLK1 phosphorylation) |
|
BRCA2 localization to the midbody by FLNA regulates CEP55 signaling and completion of cytokinesis |
|
TEX14 competitively binds to CEP55-EABR to prevent the recruitment of PDCD6IP, which is a component of the ESCRT machinery with the AxGPPx3Y motif |
|
DDX21 induces CEP55 expression, and MYCN-amplified neuroblastoma cell proliferation and tumorigenesis |
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
in colorectal cancers (CRC) as well as in tumors arising in the stomach, lung, pancreas, and breast | tumoral
|  
|  
| --over
|  
|
in hepatocellular carcinoma | tumoral
|  
|  
| --over
|  
|
overexpressed inoral squamous cell carcinomas, thus stimulating cell migration and invasion through increased FOXM1 and MMP2 expression | |